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Abstract
Protein-energy wasting (PEW) is a syndrome that consists of metabolic and nutritional abnormalities that often
occur in chronic kidney disease (CKD), and PEW has been found to be associated with increased morbidity and
mortality. A review was conducted to identify publications detailing the pathophysiology and management of PEW
in CKD. The International Society of Renal Nutrition and Metabolism (ISRNM) has recently published the consensus
statement of current knowledge regarding the etiology of PEW in CKD. Although insufficient food intake due to
poor appetite and dietary restrictions contributes to the development of PEW, many other factors must be present
for PEW to develop. The others include uremia-induced alterations such as increased energy expenditure, chronic
inflammation, metabolic acidosis, and endocrine disorders that lead to a state of hypermetabolism and result in
excess muscle and fat catabolism. In addition, comorbid conditions associated with CKD, low physical activity, frailty,
and dialysis itself also contribute to the development of PEW. Serial assessments of the nutritional status of CKD
patients by means of several scoring tools, including the Subjective Global Assessment (SGA), Malnutrition
Inflammation Score (MIS), Geriatric Nutritional Risk Index (GNRI), and PEW diagnostic criteria, are recommended to
diagnose and manage PEW. This review summarized recent advances in the etiology and evaluation of PEW of CKD
patients. However, there are few treatment options for PEW with proven efficacy in terms of improved quality of
life, morbidity, and mortality. Proposed therapeutic interventions need to be evaluated in randomized controlled
trials to determine whether they improve clinically relevant outcomes.
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Background
The concept of protein-energy wasting (PEW) was pro-
posed by the International Society of Renal Nutrition
and Metabolism (ISRNM) in 2007 [1]. PEW is a syn-
drome that consists of nutritional and metabolic abnor-
malities that are common in patients with chronic
kidney disease (CKD), especially in those with end-stage
renal disease (ESRD), and it is associated with high mor-
bidity and mortality. Although insufficient food intake
due to poor appetite and dietary restrictions contributes
to malnutrition, the pathophysiology of PEW cannot be
fully explained by undernutrition. As shown in Table 1,
PEW is thought to be attributable to many factors, in-
cluding aging, hypercatabolic status, increased resting
energy expenditure (REE), uremic toxins, malnutrition,
chronic inflammation, and acidosis [2]. This review art-
icle summarizes recent advances in the pathophysiology
and management of PEW in CKD patients.
Pathophysiology of PEW
Undernutrition and appetite loss
Low energy and/or protein intake was found to be asso-
ciated with a significant decline in nutritional parame-
ters such as the serum albumin levels and a higher
increased risk of morbidity and mortality in patients
with advanced CKD [3, 4]. Although restriction of diet-
ary sodium, phosphate, potassium, and fluid intake pre-
vents complications, dietary therapy may not be
effective when dietary restrictions are unaccompanied
by a dietitian’s instruction in regard to alternative food
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choices and/or strategies to ensure adequate nutrient
intake [5, 6].
Appetite loss often leads to inadequate protein and
energy intake and contributes to poor quality of life
[7, 8], and the prevalence of appetite loss among ESRD
patients has been reported to be 35 to 50 % [9, 10]. A
spontaneous decrease in food intake occurs during a
progressive decline in kidney function, and the decline
is correlated with accumulation of nitrogen-derived
uremic toxins [11, 12]. Factors that affect food intake in-
volve not only metabolic disturbances but abnormalities
of the digestive system [13].
Decreased energy intake results in reduced insulin
secretion, which stimulates the gluconeogenesis from
glycogen and increases fatty acid mobilization, and it
contributes to a reduction in basal metabolic rate
[14]. Muscle mass is preserved because of increased
insulin sensitivity, and diets containing as little as
0.55 g/kg/day of protein may be well tolerated [15].
However, serum prealbumin and albumin levels have
increased half-life, and their concentration as a result
of moderate calorie or protein restriction does not
change [16, 17].
Hypermetabolism
Increased REE
The REE of CKD patients is usually normal but it in-
creases from 12 to 20 % during a hemodialysis (HD) ses-
sion [18] or when there are comorbidities such as poorly
controlled diabetes [19], severe hyperparathyroidism [20],
and cardiovascular disease (CVD) [21]. Increased REE is
frequently mitigated by decreased physical activity, which
leads to a reduction in total energy expenditure [22, 23].
Chronic inflammation
Chronic inflammation induces muscle insulin resistance
via activation of intracellular NADPH oxidases [24], and
the inflammatory response is associated with an increase
in REE. Inflammation causes a decline in the serum albu-
min level and a reduction in the synthesis and half-life of
serum albumin [25]. The increased oxidative stress in-
duced by inflammation is associated with muscle insulin
resistance, muscle wasting, and atherosclerotic disease
[26]. Thus, chronic inflammation causes an increase in
REE and oxidative stress, leading to muscle loss.
Inflammatory markers have been reported to be in-
creased in conditions associated with muscle loss,
including in CKD [27–29]. Muscle loss due to inflamma-
tion has been found to be related to increased inflamma-
tory cytokine production [29]. A previous study showed
that high circulating interleukin (IL)-6 levels contribute
to inflammatory muscle protein losses that are triggered
by alteration of IL-6 signaling due to interaction with
acute-phase proteins such as serum amyloid A, to impair
insulin/insulin-like growth factor (IGF)-1 signaling via
the transcription 3 activator [30]. In uremic skeletal
muscle, IL-6 has also been linked to increased caspase-3
activity as the initial step in loss of muscle protein [31].
Tumor necrosis factor (TNF)-related weak inducer of
apoptosis (TWEAK), a member of the TNF superfamily
[32], binds to its receptor, Fn14, which is linked to sig-
naling pathways involved in the regulation of nuclear
factor kappa light-chain enhancer of activated B cells
(NF-κB) and to apoptotic cascades, and a significant
interaction between soluble TWEAK and IL-6 has been
found to be in the prediction of mortality and reduced
muscle strength in HD patients [33].
Humoral factors
Impairment of insulin/IGF-1 Resistance to insulin, IGF-
1, and growth hormone has been implicated as a mechan-
ism of muscle loss in adult CKD patients. Insulin or IGF-1
binds cell surface receptors that activate similar down-
stream signaling pathways, which act to prevent loss of
muscle protein [34]. Because myofiber shrinkage and satel-
lite cell fusion are regulated by insulin and IGF-1, the insu-
lin/IGF-activated signaling pathways determine the balance
Table 1 Phathogenesis of PEW in CKD patients
Causes
1. Decreased protein and energy intake
a. Anorexia
b. Dietary restrictions
c. Alterations in organs involved in nutrient intake
d. Depression
2. Hypermetabolism
a. Increased energy expenditure
(1) Inflammation
(2) Increased circulating proinflammatory cytokines
b. Hormonal disorders
(1) Insulin resistance of CKD
(2) Increased glucocorticoid activity
3. Metabolic acidosis
4. Decreased physical activity
5. Decreased anabolism
a. Resistance to GH/IGF-1
b. Low thyroid hormone levels
6. Comorbidities
a. Diabetes mellitus
b. Chronic heart failure
7. Dialysis procedure
a. Nutrient losses into dialysate
b. Dialysis-related inflammation
c. Dialysis-related hypermetabolism
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between protein synthesis and degradation, and changes in
the balance lead to overall changes in muscle mass.
The effect of low insulin concentrations on muscle
mass has been clearly described. The net protein ana-
bolic effect of insulin involves a reduction in proteolysis
more than increased protein synthesis. The alterations in
glucose metabolism that occur in association with hyper-
insulinemia and decreased tissue sensitivity to insulin
are partially correctable by HD [35, 36]. HD patients
with type 2 diabetes have a higher rate of muscle protein
loss than in the absence of diabetes [37]. Moreover, the
greater insulin resistance correlates with muscle protein
breakdown in nondiabetic HD patients [38]. Insulin re-
sistance is a major target of intervention in PEW. For
example, treatment with an insulin sensitizer (PPARγ
agonist, rosiglitazone) suppressed muscle proteolysis in
insulin-resistant mice [39]. It is not surprising that rosi-
glitazone treatment has been found to be associated with
significantly lower all-cause mortality and higher serum
albumin levels among insulin-free, but not insulin-
requiring, diabetic HD patients [40].
Uremia, inflammatory cytokines, metabolic acidosis,
glucocorticoids, and angiotensin (ANG)-II share a com-
mon mechanism as causes of muscle wasting: impairment
of insulin/IGF-1 actions by altering the signaling through
the phosphatidylinositol 3-kinase (PI3-kinase)/Akt path-
way [41, 42]. Dysfunctional PI3-kinase/Akt activity also re-
sults in activation of caspase-3, an apoptotic protease that
degrades actin from actomyosin complexes [43], and a
byproduct of this proteolytic reaction is a characteristic
actin fragment that has been shown to serve as a bio-
marker of muscle wasting in HD patients [31].
Low thyroid hormone levels There are no available data
which can distinguish whether low thyroid hormone levels
in CKD patients with PEW are an adaptation that reduces
REE and minimizes protein catabolism or an insufficient
adaptation participating in the wasting syndrome [44].
Low triiodothyronine levels in CKD stage 5 patients are
associated with systemic inflammation and endothelial
dysfunction and with high all-cause and cardiovascular
mortality [45–48]. The correlation between triiodothyron-
ine levels and mortality rates was weaker after adjustment
for serum C-reactive protein and albumin levels as surro-
gate PEW markers [49]. Thus, even if low thyroid hor-
mone participates in the PEW process, the changes in
thyroid hormone levels may act as intermediate links
among inflammation, metabolic acidosis, PEW, and mor-
tality and not as a primary cause.
Metabolic acidosis
Metabolic acidosis is a key mechanism in the starvation
response, and it induces the release of branched chain
amino acids from muscle during ketosis. It also causes
insulin resistance, which leads to loss of muscle mass.
Acidosis does not alter insulin/IGF-1 receptor binding,
but it inhibits intracellular signaling. Metabolic acidosis
induces increased adrenal glucocorticoid production, and
adrenalectomized rats exhibit much less muscle wasting
that is reserved by glucocorticoid replacement. Glucocor-
ticoids induce insulin/IGF-1 resistance in skeletal muscle
by altering the same signaling pathways that are affected
by acidosis, but they act on slightly different signaling
molecules within the pathways [50]. It is noteworthy that
prevailing evidence from other CKD comorbidities, in-
cluding ANG II and inflammation, indicates that insulin/
IGF-1 resistance and elevated serum glucocorticoid levels
are the physiological responses that cause both the in-
crease in protein catabolism and suppression of protein
synthesis [51, 52]. Investigating this coordinated response
may provide additional evidence in regard to how insulin/
IGF-1 signaling controls muscle wasting.
Comorbidities
Typical comorbidities associated with CKD or ESRD
contribute to a catabolic process and to the development
of PEW. In view of the high prevalence of diabetes melli-
tus in CKD patients, it may be the most important co-
morbidity. Pupim et al. [53] showed that diabetes is an
important predictor of the lean body mass loss of dialy-
sis patients and that reduced insulin signaling as a result
of insulin absence or resistance results in increased
muscle protein breakdown [37]. Diabetes also causes
CVD and neuropathy, both of which contribute to infec-
tion, muscle atrophy, and diabetic gastroparesis. Accord-
ing to these complications, long-term diabetic dialysis
patients no longer require hypoglycemic therapy, and
the poor outcomes in this subgroup with “burnt-out dia-
betes” may be the result of PEW [54].
CVD, especially congestive heart failure (CHF), is an-
other common comorbidity [55]. Inadequate cardiac
output drives neurohumoral responses associated with
PEW, including increased serum glucocorticoid and
ANG II levels and enhanced sympathetic nerve activity.
Right ventricular heart failure with passive congestion of
the liver and gut wall edema is associated with alter-
ations in nutrient absorption, appetite loss, and gut mu-
cosal barrier function [55, 56].
CKD mineral bone disorder (CKD-MBD) is a comor-
bid condition associated with PEW. PEW contributes to
CKD-MBD, because body weight loss, inflammation, and
physical inactivity lead to bone loss. Certain conditions as-
sociated with CKD such as protein loss and appetite loss
can predispose these patients to reduced vitamin D levels.
Low circulating vitamin D levels, a decrease in klotho, and
an increase in fibroblast growth factor-23 levels stimulate
parathyroid hormone synthesis, thereby contributing to
the development of secondary hyperparathyroidism [57].
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Vitamin D and/or parathyroid hormone have long been
considered contributors to PEW, and vitamin D appears
to play a role in some key molecular pathways involved in
PEW and muscle regulation [58]. There is a positive asso-
ciation between hypogonadism and 25-hydroxyvitamin D
levels, suggesting an additional mechanism by which vita-
min D may regulate muscle mass in males [59].
Low physical activity and frailty
Decreased physical activity is likely to play a major role
in the pathophysiology of PEW in association with in-
creased CVD mortality, because some CKD patients
with low physical activity are at increased risk of pro-
gression to CKD secondary to obesity, diabetes, and
hypertension, which lead to CVD. In addition, some
common comorbidities in CKD patients are associated
with decreased ability to exercise. Furthermore, certain
complications of CKD, including anemia, volume over-
load, and muscle wasting, limit exercise ability. Patients
with G3–G5 CKD have a lower median peak oxygen
consumption level, and it limits exercise by some pa-
tients enough to impair activities of daily living [60].
Muscle weakness as measured by grip strength and max-
imum gait speed is common in G5 CKD [61]. Lack of
exercise can increase inflammatory markers in associ-
ation with decreased muscle mass, may be associated
with mortality [62].
Dialysis procedure
Recent studies have reported how dialysis treatment af-
fects protein and energy homeostasis. Amino acid and
protein loss during dialysis sessions combined with low
nutrient intake result in low nutrient availability for
muscle synthesis [63, 64]. Catabolic effects of HD ther-
apy on protein homeostasis are profound. The net pro-
tein breakdown has been related to (1) an absolute
decline in amino acid levels due to dialysis losses, (2)
imbalances in amino acid levels, and (3) activation of
the inflammatory cascade [65]. Fortunately, concurrent
amino acid supplementation can prevent or reverse
these adverse effects in HD patients [66–68], providing
an opportunity for the treatment of PEW.
Evaluation of PEW
Serial assessments of the nutritional status of CKD
patients by means of several scoring tools, including the
Subjective Global Assessment (SGA), Malnutrition
Inflammation Score (MIS), Geriatric Nutritional Risk
Index (GNRI), and PEW diagnostic criteria, are recom-
mended to diagnose and manage of PEW. These tools
are reliable, and they are useful to determine predictors
of outcomes in CKD patients.
Subjective Global Assessment (SGA)
Baker et al. reported the finding that a general clinical
assessment was a reproducible and valid tool of evaluat-
ing nutritional status, a process later referred to as the
Subjective Global Assessment (SGA) tool [69]. A more
detailed description of the semiquantitative scoring sys-
tem of SGA, which is based on the medical history and
physical examination, was later published by Detsky
et al. [70]. As shown in Table 2, the medical history con-
sisted of 5 components: weight loss during the preceding
6 months, gastrointestinal symptoms, food intake, func-
tional capacity, and comorbidities. The physical examin-
ation consisted of 2 components: loss of subcutaneous
fat and muscle wasting. Each component was scored on
a scale from 0 to 3, representing normal to severely ab-
normal. Each of these features were graded separately as
A, B, or C, reflecting well-nourished to severely mal-
nourished categories.
A proposed modified SGA tool emerged from the
CANUSA (Canada-USA) study in 1996 in which the fol-
lowing 4 items were scored on a 7-point Likert-type
scale, with lower scores assigned to poor nutritional sta-
tus: 1 = weight loss during the past 6 months, 2 = an-
orexia, 3 = subcutaneous fat, and 4 = muscle mass; and
scoring was as follows: 1 to 2 = severe malnutrition, 3 to
5 = moderate to mild malnutrition, and 6 to 7 = normal
nutrition [71]. A modified quantitative SGA called the
Dialysis Malnutrition Score (DMS) was proposed in
1999 by Kalantar-Zadeh et al. [72] and consists of 7
components: weight change, dietary intake, gastrointes-
tinal symptoms, functional capacity, comorbidities, sub-
cutaneous fat, and muscle wasting.
Malnutrition inflammation score (MIS)
Because of the recognition of the role of inflammation
in causing PEW and in an attempt to make their scoring
system more comprehensive and quantitative, the same
group revised the criteria for the 7 DMS components
and added 3 new items: body mass index, serum albu-
min level, and total iron-binding capacity (Table 3). This
new score was called the Malnutrition Inflammation
Score (MIS) [73].
Geriatric Nutritional Risk Index (GNRI)
It has been pointed out that there are simpler and more
objective nutritional assessments that have been
developed for special situations such as hospitalized,
postoperative, and elderly patients. These methods in-
clude the Mini Nutritional Assessment Short Form,
Nutrition Risk Score, Malnutrition Universal Screening
Tool, Malnutrition Screening Tool (MST), and Geriatric
Nutritional Risk Index (GNRI) [74, 75].
The GNRI was proposed because current methods of
nutritional evaluation used several subjective assessments
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Table 2 Evaluation of subjective global assessment (SGA)
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and judgments, and assessment by a well-trained staff is
necessary to obtain consistent results across examiners
and institutions. Furthermore, the other methods were
somewhat time-consuming and cumbersome. As shown
in Table 4, the GNRI was intended to be a more simple
method of assessing nutritional status that was based on
only 3 objective parameters, body weight, height, and
serum albumin levels, whose values are used to calculate
Table 3 Components of the malnutrition inflammation score (MIS)
Malnutrition Inflammation Score
(A) Patient’s related medical history
1- Change in end dialysis dry weight history:
0 1 2 3
No decrease in dry weight or
weight loss <0.5 kg
Minor weight loss (≥0.5 kg but
<1 kg)
Weight loss more than 1 kg but <5 % Weight loss >5 %
2- Dietary intake:
0 1 2 3
Good appetite and no deterioration
of the dietary intake pattern
Somewhat sub-optimal solid diet
intake
Moderate overall decrease to full
liquid diet
Hypo-caloric liquid to starvation
3- Gastrointestinal (GI) symptoms:
0 1 2 3
No symptoms with good appetite Mild symptoms, poor appetite or
nauseated occasionally
Occasional vomiting or moderate GI
symptoms
Frequent diarrhea or vomiting or
severe anorexia
4- Functional capacity (nutritionally related functional impairment):
0 1 2 3
Normal to improved functional
capacity, feeling fine
Occasional difficulty with baseline
ambulation, or feeling tired frequently
Difficulty with otherwise independent
activities (e.g., going to the bathroom)
Bed/chair-ridden, or little to
no physical activity
5- Comorbidity including number of years on dialysis:
0 1 2 3
On dialysis less than 1 year and
healthy otherwise
Dialyzed for 1–4 years, or mild
comorbidity (excluding MCCa)
Dialyzed >4 years, or moderate
comorbidity (including one MCCa)
Any severe, multiple comorbidity
(2 or more MCCa)
(B) Physical exam (according to SGA criteria):
6- Decrease fat stores or loss of subcutaneous fat (below eyes, triceps, biceps, chest):
0 1 2 3
Normal (no change) Mild Moderate Severe
7- Signs of muscle wasting (temple, clavicle, scapula, ribs, quadriceps, knee, interosseous):
0 1 2 3
Normal (no change) Mild Moderate Severe
(C) Body mass index:
8- Body mass index: BMI = Wt (kg)/Ht2 (m)
0 1 2 3
BMI ≥20 kg/m2 BMI 18–19.99 kg/m2 BMI 16–17.99 kg/m2 BMI <16 kg/m2
(D) Laboratory parameters:
9- Serum albumin:
0 1 2 3
Albumin ≥4.0 g/dL Albumin 3.5–3.9 g/dL Albumin 3.0–3.4 g/dL Albumin <3.0 g/dL
10- Serum TIBC (total iron-binding capacity): ♣
0 1 2 3
TIBC ≥250 mg/dL TIBC 200–249 mg/dL TIBC 150–199 mg/dL TIBC <150 mg/dL
Total score = sum of above 10 components (0–30)
aMCCs (major comorbid conditions) include CHF class III or class IV, full-blown AIDS, severe CAD, moderate to severe COPD, major neurological sequelae, and
metastatic malignancies or s/p recent chemotherapy
♣Suggested equivalent increments for serum transferrin are: > 200 (0), 170-199 (1), 140-169 (2) and < 140 (3) mg/dL
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the index by the following formula: GNRI = (14.89 × albu-
min g/dL) + [41.7 + (body weight/ideal body weight)] [75].
Yamada et al. reported the finding that the GNRI was a
useful tool for assessing the nutritional status not only of
elderly patients but also of HD patients [76].
A simple PEW score
Moreau-Gaudry et al. recently reported a new PEW
scoring system based on simple, readily available param-
eters and showed that it can predict survival in mainten-
ance HD patients with acceptable accuracy [77]. As
shown in Table 5, the PEW score includes 1 parameter
from each major group generally identified as interfering
with CKD patients’ nutritional status: (1) biological pa-
rameters (serum albumin), (2) body composition (body
mass index), (3) muscle mass (serum creatinine/body
surface area), and (4) nutrient intake (normalized protein
catabolic rate). Muscle mass, which accounts for the
major part of body mass, is strongly associated with sur-
vival. They chose to use the predialysis serum creatinine
level normalized to body surface area. However, the reli-
ability of this score has not been validated.
Diagnosis of PEW
The clinical diagnostic criteria proposed for PEW in
CKD are listed in Table 6. The expert panel of the
ISRNM recommended that 4 main established categories
be recognized for the diagnosis of PEW: biochemical cri-
teria; low body weight, reduced total body fat, or weight
loss; a decrease in muscle mass; and low protein or en-
ergy intake. At least 3 of the 4 listed categories (and at
least 1 test result in each of the selected categories) must
be satisfied for the diagnosis of CKD-related PEW.
Ideally, each criterion should be documented on at least
3 occasions, preferably 2 to 4 weeks apart [78].
Among the biochemical criteria, it is recommended
that at least 1 indicator be included when making the
clinical diagnosis of PEW: serum albumin level
<3.8 g/dL, serum transthyretin level <30 mg/dL, or
serum cholesterol level <100 mg/dL. There appears to
be a consensus among other organizations to recom-
mend serial nutritional assessment by SGA in HD pa-
tients. As’habi et al. have recently reported the
comparison of various scoring methods for the diag-
nosis of PEW in HD patients [79]. They investigated
the cutoff points for the diagnosis of mild-to-
moderate and severe PEW based on DMS and MIS
and the sensitivity, specificity, accuracy, and area
under receiver operating characteristic curve analysis
of these scores in comparison with SGA. The results
of their study indicated that the DMS and MIS were
almost similar to SGA for identifying PEW in HD
patients.
Management of PEW
Multiple treatment strategies against the etiologies may
be required to prevent or reverse PEW [78].
Table 4 Assessment of geriatric nutritional risk index (GNRI)
Formula
GNRI = [14.89 × albumin (g/dL)] + 41.7 × (body weight/ideal body weight)]
Ideal weight in this study was calculated from the Lorentz equations for men
and women differently, as in the original GNRI equation
Table 6 A proposed criteria for the clinical diagnosis of PEW in
CKD patients
Criteria
Serum chemistry
Serum albumin <3.8 g/dLa
Serum prealbumin (transthyretin) <30 mg/dL (for maintenance dialysis)
Serum cholesterol <100 mg/dLa
Body mass
Body mass index (BMI) <23b
Unintentional weight loss over time: 5 % over 3 months or 10 % over
6 months
Total body fat percentage <10 %
Muscle mass
Reduced muscle mass 5 % over 3 months or 10 % over 6 months
Reduced mid-arm muscle circumference areac (reduction >10 % in
relation to the 50th percentile of reference population)
Creatinine appearanced
Dietary intake
Unintentional low dietary protein intake <0.80 g/kg/day for at least
2 monthse for dialysis patients or <0.6 g/kg/day for patients with CKD
G2-5
Unintentional low dietary energy intake <25 kcal/kg/day for at least
2 months
At least three of the four listed categories along with at least one test in each
of the selected categories must be satisfied for the diagnosis of CKD-related
PEW. Each criterion should be documented on at least three occasions, preferably
2–4 weeks apart
aNot valid in abnormally great urinary or gastrointestinal protein losses, liver
disease, or cholesterol-lowering medications
bA lower BMI might be favorable in certain Asian populations
cMeasurement must be performed by a trained anthropometrist
dCreatinine appearance is influenced by both muscle mass and meat intake
eCan be assesed by dietary diaries and interview, or for protein intake by
calculation of normalized protein equivalent of total nitrogen appearance
(nPNA or nPCR) as determined by urea kinetic measurements
Table 5 Definition of a simple protein-energy wasting score
Serum albumin (g/dL) ≤3.8
Body mass index (kg/m2) ≤23
SCr/BSA (μmol/L/m2) ≤380
nPNA (g/kg/day) ≤0.8
nPNA normalized protein nitrogen appearance, Scr/BSA predialysis serum
creatinine/body surface area (using postdialysis body weight)
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Individualized, continuous nutritional counseling,
optimization of the dialysis regimen, prevention or cor-
rection of muscle wasting, and management of comor-
bidities (e.g., metabolic acidosis, diabetes, infection, CHF,
and depression) are the most essential preventive mea-
sures. Oral or parenteral nutrition supplements together
with appetite stimulants and muscle-enhancing agents
should be prescribed for patients whose protein and en-
ergy stores are not sustained despite those efforts.
Dietary interventions
As shown in Table 7, dietary protein intake of 0.6–0.8 g/
kg/day and energy intakes of 30–35 kcal/kg/day have
been recommended for patients with stage G3b-5 CKD
(estimated glomerular filtration rate (GFR) <45 ml/min/
1.73 m2 body surface area (BSA)), because there is evi-
dence that a low-protein diet (LPD) slows the progres-
sion of advanced CKD to ESRD and may mitigate
uremia [80]. However, it is difficult to implement proper
protein restriction for CKD patients, and inadequate en-
ergy intake is considered a common reason for protein
restriction failure and may lead to PEW [80]. Partly be-
cause of this concern, an LPD has not been widely used
in clinical settings in the USA, Europe, and some indus-
trialized nations. To address this issue, Wu et al. con-
ducted an open-label randomized controlled study of
energy supplementation in patients with stage G3-4
CKD on an LPD. They found that a supplement packet
containing 40 g of maltodextrin and 5 g of oil creamer
at breakfast significantly decreased protein intake esti-
mated by 24-h urinary urea excretion by a mean of
0.13 g/kg/day and resulted in lower urinary protein ex-
cretion and a higher estimated GFR [81]. Their findings
indicated that energy supplementation may improve ad-
herence to LPD in addition to preventing the develop-
ment of PEW.
Another study that combined epidemiologic and ex-
perimental investigations revealed that the effect of pro-
tein intake on health may vary according to age [82]. In
this analysis of the National Health and Nutrition Exam-
ination Survey III, participants aged 50–65 years who
had reported high protein intake were found to be at
higher risk of all-cause death and cancer death, and high
protein intake was found to be associated with lower all-
cause and cancer mortality in the group of 65 years of
age and over. The results of mouse model studies also
convincingly supported these findings. Since the elderly
patients account for a significant proportion of CKD pa-
tients, these findings suggest that nephrologists and die-
titians should take the patients’ age into consideration
when deciding the extent to which dietary protein
should be restricted, because elderly CKD patients are
generally frail and at higher risk of death than of pro-
gression to ESRD.
In contrast to nondialysis CKD patients, much
higher protein intake (>1.2 g/kg/day, i.e., twice as
high as for nondialysis CKD patients) is recom-
mended for ESRD patients on dialysis for the follow-
ing three reasons: first, there is no need to mitigate
uremia by protein restriction after starting the patient
on dialysis, second, dialysis ameliorates the metabolic
acidosis induced by protein intake, and third, the dia-
lysis procedure further stimulates protein catabolism
[78]. Indeed, low protein intake, as reflected by a
low normalized protein catabolic rate or low protein
nitrogen appearance, is associated with high mortal-
ity in this population, and protein intake does not
reach the recommended level in many patients [83,
84]. Oral or parenteral nutritional supplementation
should be prescribed when dialysis patients exhibit
evidence of malnutrition despite standard preventive
measures. Several studies have demonstrated that
standard preventive measures improve nutritional
parameters such as lean body mass and the serum
albumin concentration [85], and the results of recent
observational studies have suggested that oral nutri-
tional supplement use results in a decrease in
hospitalization rates [86] and mortality [87].
Phosphate control
Phosphate is considered a uremic toxin. Indeed, hyper-
phosphatemia is an established risk factor for CVD and
Table 7 Recommended minimum protein, energy, and mineral intakes for chronic kidney disease (CKD) and maintenance dialysis
patients
Nondialysis CKD Hemodialysis Peritoneal dialysis
Protein 0.6–0.8 g/kg/day >1.2 g/kg/day >1.2 g/kg/day
Illness 1.0 g/kg Peritonitis >1.5 g/kg
Energy 30–35a kcal/kg/day 30–35a kcal/kg/day 30–35a kcal/kg/day including kcal from dialysate
Sodium 80–100 mmol/day 80–100 mmol/day 80–100 mmol/day
Potassium <1 mmol/kg if elevated <1 mmol/kg if elevated Not usually an issue
Phosphorus 800–1000 mg and binders if elevated 800–1000 mg and binders if elevated 800–1000 mg and binders if elevated
Greater than 50 % of high biological value protein (that is, complete protein sources, containing the full spectrum of essential amino acids) is recommended
aBased on physical activity level. In sedentary elderly adults, recommended energy intake is 30 kcal/kg/day. All recommendations are based on ideal body weight.
Regular follow-up supports compliance
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death in CKD patients [88], and phosphate binders, es-
pecially binders that do not contain calcium, mitigate
vascular calcification and thus decrease the rate of
CVD and death [89]. Interestingly, although the dietary
protein levels of ESRD patients are generally correlated
with their dietary phosphate content and associated
with serum phosphate concentration [90], high serum
phosphorus concentrations are consistently associated
with high mortality among HD patients [91], in con-
trast to the abovementioned association of protein in-
take with death.
This discrepancy may be explained by the link between
phosphate and PEW. In a study on rats with adenine-
induced CKD, Yamada et al. [92] showed that dietary
phosphate induces systemic inflammation and oxidative
stress dose-dependently without affecting kidney func-
tion and resulted in the development of phenotypes of
PEW that included weight loss, hypoalbuminemia, and
decreased urinary creatinine excretion. Moreover, a high
phosphate diet caused vascular calcification and prema-
ture death. Administration of lanthanum carbonate, a
non-calcium-containing phosphorus binder, ameliorated
almost all of these pathological changes. Thus, the results
of the study reinforced the importance of phosphate man-
agement in CKD highlighting the novel association be-
tween hyperphosphatemia and PEW. However, neither
phosphate binders nor dietary restriction can be advocated
as a means of preventing or treating PEW until similar
data become available for humans. Indeed, phosphate re-
striction is potentially harmful for ESRD patients on dialy-
sis, because it is often accompanied by a reduction in
protein intake, which results in adverse outcomes caused
by the development of PEW [78].
Exercise
Dialysis patients often exhibit extremely low physical ac-
tivity, and the resultant muscle disuse is an underrepre-
sented risk factor for muscle wasting [93, 94]. This
finding is important, because exercise interventions can
prevent or even reverse muscle wasting. Indeed, a recent
systematic review of the literature confirmed that pro-
gressive resistance training induces skeletal muscle
hypertrophy, increases muscular strength, and improves
their health-related quality of life of CKD patients [95].
A single randomized trial found that the anabolic and
strength responses are similar between healthy partici-
pants and hemodialysis patients [96]. Although the long-
term effect of resistance exercise training on clinically
relevant outcomes is yet to be determined, it is well toler-
ated, effective, and cost-free and should be encouraged as
a potential preventive measure against PEW. In advanced
CKD, bicarbonate supplementation might enhance the
anabolic effects of progressive resistance training by miti-
gating exercise-induced lactic acidosis [97].
Dialysis procedure
Dialysis adequacy has been considered a target measure to
prevent and treat PEW in maintenance dialysis patients,
and the minimum dialysis dose has been recommended to
maintain optimal dietary nutrient intake. On the other
hand, few studies have directly evaluated the effect of in-
creased dialysis dose on nutritional parameters. The re-
sults of the National Cooperative Dialysis Study showed
an association between lower protein intake and higher
time-averaged urea concentrations, suggesting a relation-
ship between underdialysis and appetite loss [98]. Several
subsequent studies have suggested that protein nitrogen
appearance is dependent on the type and the dose of dia-
lysis [99, 100]. However, none of these retrospective and/
or cross-sectional studies demonstrated a cause-effect re-
lationship between dialysis dose and nutritional status. In
the HEMO study, the higher delivered dialysis dose (eKt/
V 1.53 ± 0.09) neither prevented nor reversed the declines
in several indices of nutritional status in maintenance HD
patients as compared with the conventional dialysis dose
(eKt/V 1.16 ± 0.08). Thus, it can be concluded that what is
currently considered adequate dialysis in various guide-
lines is sufficient to maintain the nutritional status of HD
patients [101]. Increasing the dialysis dose beyond these
targets has not been shown to improve nutritional status.
Dialysis membrane characteristics may have important
implications for the nutritional management of mainten-
ance HD patients. Middle molecules, such as β2-
microglobulin, are more efficiently removed by high-flux
dialyzers than low-flux dialyzers, although no significant
differences in most of the nutritional parameters studied
were found between the two groups in the HEMO trial
[102]. The European MPO trial investigated the effects
of high-flux versus low-flux dialysis in maintenance HD
patients. Although there was no difference in the patient
group as a whole, there was a nominally significant sur-
vival benefit in the group with baseline serum albumin
levels <40 g/L and in the group with diabetes mellitus
that were randomized to high-flux dialysis [103].
The effects of an increase in dialysis frequency on vari-
ous outcome measures have been reported by nonrando-
mized studies and suggest that daily dialysis increases
appetite, protein and energy intake, body weight after
hemodialysis, interdialytic weight gain, the serum albu-
min level, normalized protein nitrogen appearance, and
the serum cholesterol [104]. However, the results of the
FHN trial showed no appreciable differences in nutri-
tional markers between subjects randomized to 6×/week
in-center hemodialysis versus standard 3×/week in-
center HD [105]. Hemodiafiltration has also been pro-
moted as an efficient method of removing uremic toxins,
but no randomized prospective studies have been pub-
lished of the effects of hemodiafiltration on nutritional
parameters [106].
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Conclusions
Recent studies have shown that advances in knowledge
of how inflammation, insulin resistance, oxidative stress,
glucocorticoids, and metabolic acidosis modify the re-
sponse to reduced protein and energy intake to under-
stand the pathophysiology of PEW. Although HD therapy
improves uremia, residual metabolic derangements, in-
flammation, and comorbid conditions, the dialysis itself is
insufficient to treat PEW. Evaluating reduced protein and
energy intake and comorbidities separately enable to clar-
ify the pathogenesis of PEW. Evaluation, prevention, and
treatment of PEW should involve individualized ap-
proaches specific to the CKD population. Nevertheless,
there are few treatment options with proven efficacy in
terms of quality of life, morbidity, and mortality. Proposed
therapeutic interventions need to be evaluated in random-
ized controlled trials to determine whether they improve
clinically relevant outcomes.
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